The Day In Review: Threshold Pharmaceuticals, Inc. Reports Success Against Pancreatic Cancer

December 28, 2006 -- Threshold rose 28% after announcing positive data for its pancreatic cancer drug; SciClone asked for approval in China to market DC Bead, a treatment for liver cancer; Keryx began a Phase I trial of KRX-0401 for multiple myeloma; MedImmune in-licensed a pathway implicated in inflammatory diseases from Japan Tobacco; BioSante began a Phase III trial of a female sexual dysfunction gel; Array BioPharma will begin a Phase I trial of cancer drug ARRY-520; Bioenvision will file for a label extension of Evoltra to include adult AML patients; in a journal article, GlaxoSmithKline presented positive data for Tykerb, its breast cancer treatment; and Encysive fell on news the FDA will take six months to rule on Thelin. The Centient Biotech 200™ rose a very modest 4 points to 3934, a gain of .11%. More details...